SCHEMBL6788914

SCHEMBL6788914

CCC1(O)C(=O)Cc2c1cc1n(c2=O)Cc2cc3cc(C)c(C)cc3nc2-1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 18/20 0.60
DDX5 P17844 1/20 0.60
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
KDM4E B2RXH2 3/20 0.58
ALDH1A1 P00352 3/20 0.58
CYP3A4 P08684 2/20 0.58
HBB P68871 2/20 0.58
CASP1 P29466 1/20 0.58
CASP7 P55210 1/20 0.58
TP53 P04637 2/20 0.57
GLA P06280 2/20 0.57
HPGD P15428 2/20 0.57
STAT6 P42226 1/20 0.57
CHEK1 O14757 1/20 0.57
HDAC3 O15379 1/20 0.57
ABCC4 O15439 1/20 0.57
GMNN O75496 1/20 0.57
LMNA P02545 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6782602 0.92 TOP1 (0.58) TOP1DDX5MEN1KMT2ASMN1; SMN2
SCHEMBL6792999 0.89 TOP1 (0.61) TOP1DDX5MEN1KMT2ASMN1; SMN2
SCHEMBL6786007 0.86 TOP1 (0.80) TOP1DDX5MEN1KMT2ASMN1; SMN2
SCHEMBL6789515 0.86 TOP1 (0.76) TOP1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL6794534 0.85 TOP1 (0.77) TOP1DDX5MEN1KMT2ASMN1; SMN2
SCHEMBL6783214 0.80 TOP1 (0.61) TOP1DDX5MEN1KMT2ASMN1; SMN2
SCHEMBL30805390 0.80 TOP1 (0.78) TOP1DDX5MEN1KMT2ASMN1; SMN2
SCHEMBL22598074 0.80 TOP1 (0.78) TOP1DDX5MEN1KMT2ASMN1; SMN2
SCHEMBL34463611 0.80 TOP1 (0.78) TOP1DDX5MEN1KMT2ASMN1; SMN2
SCHEMBL16812223 0.78 TOP1 (0.59) TOP1DDX5MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699876-B2 FOR CANCER THERAPY LES LABORATOIRES SERVIER (FR) 2004-03-02 US disclosed
US-20030105109-A1 For cancer therapy LES LABORATOIRES SERVIER (FR) 2003-06-05 US disclosed
US-6509345-B2 For therapy of cancerous diseases LES LABORATOIRES SERVIER (FR) 2003-01-21 US disclosed
EP-1101765-B1 Camptothecin analogues, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2002-08-14 EP disclosed
US-20020077325-A1 New camptothecin analogue compounds LAVIELLE GILBERT (FR) 2002-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105109-A1 For cancer therapy OXER1, OXGR1, CBR1 TOP1 360/4885DDX5 3463/4885MEN1 4478/4885
US-20020077325-A1 New camptothecin analogue compounds OXER1, CBR3, CBR1 TOP1 18/4885DDX5 2187/4885MEN1 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.